ARPA-H’s PROSPR program directs over $50 million to aging trials, advancing drugs like Cambrian’s rapamycin analog and Linnaeus’s GPER-targeter, signaling a shift in treating aging a...
Recent research reveals that depleting gut microbiota in aged mice improves brain structure and function, highlighting the gut-brain axis as a key target for anti-aging therapies. Manipulating gut mic...
Recent advancements in cellular reprogramming, including significant funding and clinical trials, are transforming anti-aging science by targeting root causes of age-related diseases. Cellular reprogr...
Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
Recent studies show targeted epigenetic reprogramming with Yamanaka factors rejuvenates neurons, reversing cognitive decline in aged mice and reducing Alzheimer’s markers, with AI enhancing safe...
Analytical post exploring CAR-T cell therapy’s potential to treat Alzheimer’s by targeting amyloid plaques, with insights from recent clinical trials and cost-benefit considerations. Innov...
New research identifies IRF7 as a critical driver of unstable atherosclerotic plaques, offering a potential therapeutic target to reduce cardiovascular events through innovative clinical trials and te...
Recent studies reveal CAR-T cells with lecanemab antibodies reduce amyloid plaques in mice, highlighting a shift towards personalized cell-based therapies for Alzheimer’s treatment. New research...
A 2024 study in Nature Aging shows transferring young gut bacteria to aged mice rejuvenates intestinal stem cells via Wnt signaling, suggesting FMT’s potential for age-related disorders. Recent ...
A Nature Aging study shows mitochondrial stress enhances senolytic drugs like navitoclax, improving senescent cell removal by 40% with metabolic interventions. New research reveals mitochondrial stres...
